Form 4: Immunome CTO Buys 10,000 Shares
Insider Transaction Report
Immunome Inc.'s Chief Technical Officer, Philip Tsai, acquired 10,000 shares of common stock at $20.49 per share.
Summary
- Philip Tsai, the Chief Technical Officer of Immunome Inc. (IMNM), purchased 10,000 shares of the company's common stock.
- The transaction occurred on December 19, 2025, with each share acquired at a price of $20.49.
- Following this purchase, Mr. Tsai directly beneficially owns a total of 43,300 shares of Immunome Inc. common stock.
- The transaction was made pursuant to a Rule 10b5-1 trading plan.
Sentiment
Score: 7
Explanation: The sentiment is positive due to a significant insider purchase by a key executive, indicating confidence in the company's future performance and valuation.
Positives
- Insider buying by a key executive like the Chief Technical Officer can signal management's confidence in the company's future prospects and valuation.
- The purchase of 10,000 shares at $20.49 represents a significant personal investment by Mr. Tsai.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance, but the insider purchase may implicitly suggest a positive outlook from management.
Industry Context
Insider purchases, particularly by high-ranking executives, are often viewed by the market as a positive indicator, suggesting that those with the most intimate knowledge of the company believe its stock is undervalued or poised for growth. This transaction aligns with a general trend where insider activity is closely monitored for signals regarding a company's health and future direction.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transaction was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities. | 12/19/2025 | A Rule 10b5-1 plan provides an affirmative defense against insider trading allegations by establishing a pre-arranged trading schedule, demonstrating that the insider's trades were not based on material non-public information at the time of the trade. |
Stakeholder Impact
- Shareholders may interpret the Chief Technical Officer's purchase as a strong vote of confidence in Immunome Inc.'s future, potentially leading to increased investor interest and positive sentiment towards the stock.
Key Dates
| Date | Description |
|---|---|
| 12/19/2025 | Date of transaction where Philip Tsai acquired 10,000 shares of common stock. |
| 12/22/2025 | Date the Form 4 filing was signed and submitted. |
Recommendation
buyThe direct purchase of 10,000 shares by the Chief Technical Officer at a notable price of $20.49 per share is a strong positive signal. Insider buying often indicates that management, who possess the most comprehensive understanding of the company's operations and prospects, believes the stock is undervalued or has significant upside potential. This action suggests confidence in Immunome Inc.'s future, making it a favorable indicator for potential investors.
Keywords
Immunome, IMNM, Insider Trading, Form 4, Stock Purchase, Philip Tsai, CTO, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.